INTRODUCTION

Gastric cancer (GC) is the fifth most frequently diagnosed cancer and the third leading cause of cancer death worldwide [1]. Despite efforts to improve diagnostic techniques and patient management, the 5-year overall survival (OS) rate for patients with GC remains unsatisfactory because lots of patients are diagnosed at an advanced stage accompanied by lymphatic metastasis [2, 3]. Thus, a better understanding of the mechanisms underlying GC occurrence and progression is essential for improving diagnosis and treatment of the disease.

Recent advances in whole-genome sequencing technology have led to the discovery of a new class of regulatory RNAs, i.e. long noncoding RNAs (lncRNAs), which are defined as transcribed RNA molecules longer than 200 nucleotides and lacking protein-coding capacity [4, 5]. Emerging evidence suggests that lncRNAs may play critical roles in cellular development, differentiation, and many other biological processes [4–7]. The aberrant expression of lncRNAs has also been shown in various malignancies including GC [8–10]. In addition, lncRNAs may mediate oncogenic or oncosuppressive effects and may be cancer biomarkers.
and therapeutic targets [9]. Molecular mechanisms of IncRNAs are diverse. They have been shown to regulate gene expression by executing as signals, decoys, guides and scaffolds [5, 8, 10]. For example, metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) functions as a competing endogenous RNA (ceRNA) to attenuate the inhibitory effect of miR-23b-3p on autophagy-related protein 12 (ATG12), and then leads to chemo-induced autophagy and chemoresistance in GC [11]. In contrast, IncRNA GASS enhances G1 cell cycle arrest via binding to YBX1 to regulate p21 expression in GC [12].

Of the diverse array of putative molecular and biological functions assigned to IncRNAs, one attractive perspective in epigenetic research has been the hypothesis that IncRNAs directly interact with the proteins involved in the modulation of chromatin conformation. Epigenetic modifiers are among the most frequent protein partners of IncRNAs that have been identified to date, of which histone methyltransferases and protein members of the polycomb repressive complex 2 (PRC2) have received considerable attention [13]. Indeed, it has been reported that approximately 20% of all human IncRNAs act to physically associate with PRC2, suggesting that IncRNAs may have a general role in recruiting PRC2 to their target genes [14]. We have also previously reported that IncRNA SNHG17 acts to interact with PRC2, thereby promoting cell cycle progression and proliferation of GC cells by epigenetic silencing of the major cyclin-dependent kinase inhibitors (CKIs) including p15 and p57 [15]. Other epigenetic modifiers including LSD1, SMYD3, WDR5, KMT2C, SET1C, ING2 and PAQR3 may also function as potential partners for IncRNA [16–18]. For example, the interaction of IncRNA EZR-AS1 with SMYD3 has been shown to enhance SMYD3-dependent histone H3 lysine 4 (H3K4) methylation and activate EZR transcription in esophageal squamous cell carcinoma (ESCC) [17]. Besides, IncRNA HOXD-AS1 recruits WDR5 to directly regulate the expression of target genes by mediating H3K4 tri-methylation [18]. Though a small portion of IncRNAs have been functionally characterized in epigenetic modulation, many members in this class remain uncharacterized and associated research is still urgently needed.

The Rho GTPase activating protein (ARHGAP) family is a class of Rho homologous GTPase activating proteins that cause tumor formation through the dysregulation of Rho/Rac/Cdc42-like GTPases [19]. Emerging evidence has demonstrated crucial roles of ARHGAP family in the tumorigenesis and progression of diverse cancers. For example, ARHGAP1 is a factor comprising GTPase-activating protein, which enhances intrinsic GTPase activity, leading to G protein inactivation. ARHGAP1 has been shown to regulate the epithelial-to-mesenchymal transition (EMT) by inhibiting RhoA/ROCK signaling [20]. ARHGAP20 gene is located within the 11q23.1 commonly deleted region of breast cancer [21]. Besides, ARHGAP8 acts to promote the development of colorectal cancer (CRC) by encoding a novel RHOGAP with a unique functional domain [22]. ARHGAP30 induces apoptosis of CRC cells by regulating the expression of p300 to promote p53 acetylation and functional activation [23]. Located within chromosome 17q24.1, ARHGAP27 pseudogene 1 (ARHGAP27P1) is a pseudogene-derived IncRNA with a length of 2891 nt. In general, pseudogenes are dysfunctional copies of protein-coding genes, representing an intriguing class of IncRNAs. Traditionally considered as “genomic junk”, recent researches have pointed towards a functional role of many pseudogenes in tumorigenesis or tumor suppression. For example, PTEN pseudogene 1 (PTENP1) may downregulate the expression of PTEN by recruiting DNA methyltransferase 3a, thereby inhibiting apoptosis of GC cells [24]. Using RNA-sequencing data from two cohorts of lung adenocarcinoma patients, Stewart GL et al. discovered 104 deregulated pseudogene-derived IncRNAs, many of which are expressed from the loci of pseudogenes related to known cancer genes [25]. Their findings further suggest the IncRNA-pseudogene-protein-coding gene axis as a prominent mechanism of cancer gene regulation in lung adenocarcinoma. Besides executing as a synergistic or antagonistic cofactor of its parental genes, many other mechanisms including epigenetic regulation, alternative splicing and RNA decay have also been reported for pseudogene-derived IncRNAs in the oncogenesis of cancers [26–28].

Here, we report, for the first time, the expression pattern, function and regulatory mechanism of ARHGAP27P1 in GC. The results demonstrated that ARHGAP27P1 expression was significantly decreased in GC tissue samples and cell lines. Low ARHGAP27P1 expression was significantly correlated with advanced TNM stage and independently predicted a poor OS of GC patients. In addition, we investigated the effects of ARHGAP27P1 expression on GC cell phenotype in vitro and in vivo with the gain- and loss-of-function studies. Moreover, we also showed that ARHGAP27P1 could bind to Jumonji-domain containing 3 (JMJD3) to activate p15, p16 and p57 transcription. Consistently, silencing of JMJD3, p15, or p16 reversed the inhibitory effects of ARHGAP27P1 in cell proliferation and cell cycle progression. Therefore, this study suggests a tumor suppressor role of ARHGAP27P1 and expands our understanding of the role of IncRNAs as an epigenetic regulator in GC oncogenesis and progression.
RESULTS

Downregulation of ARHGAP27P1 was associated with advanced disease and predicted poorer prognosis

To explore the expression profile of ARHGAP27P1 in GC, we first detected ARHGAP27P1 expression levels in a cohort of 112 paired GC and adjacent noncancerous tissues by RT-qPCR. As shown in Figure 1A, the expression levels of ARHGAP27P1 were lower in tumor tissues. In addition, the expression of ARHGAP27P1 was downregulated in 64.3% (72/112) of GC tissues compared with that in the adjacent normal tissues (Figure 1B). Given that the differences between groups were not large, these results were still worth further investigation. To further explore the relationship between ARHGAP27P1 levels and clinicopathological parameters in GC patients, the patients were divided into high (n = 56, fold change ≥ median) and low (n = 56, fold change < median) expression groups according to the median value of ARHGAP27P1 levels. As shown in Table 1 and Figure 1C, lower ARHGAP27P1 levels were correlated with advanced TNM stage, increased invasion depth and lymphatic metastasis.

Figure 1. Upregulation of ARHGAP27P1 predicted advanced disease and poorer OS of GC. (A) The ARHGAP27P1 levels in GC tissues and adjacent noncancerous tissues were detected by RT-qPCR (n=112). (B) The fold change of ARHGAP27P1 expression in GC tissues compared with that in the paired noncancerous tissues for each patient. (C) The correlation between ARHGAP27P1 expression and TNM stage, invasion depth and lymphatic metastasis. (D) Kaplan-Meier analysis of OS according to ARHGAP27P1 expression levels. (E) The expression levels of plasma ARHGAP27P1 in GC patients (n=53) and healthy controls (n=53) were detected by RT-qPCR. (F) The correlation between plasma ARHGAP27P1 expression and TNM stage, invasion depth and lymphatic metastasis. (G) The ROC curve of plasma ARHGAP27P1 for diagnosis of GC. *P < 0.05, **P < 0.01, ***P < 0.001.
Table 1. Correlation between ARHGAP27P1 expression and patients’ clinicopathological parameters.

| Features                        | Number | ARHGAP27P1 |         |         | P value |
|--------------------------------|--------|------------|---------|---------|---------|
|                                |        | High n=56  | Low n=56|         |         |
| Gender                         |        |            |         |         |         |
| Male                           | 87     | 40         | 47      | 0.112   |         |
| Female                         | 25     | 16         | 9       |         |         |
| Age                            |        |            |         |         |         |
| < 60                           | 23     | 11         | 12      | 0.815   |         |
| ≥ 60                           | 89     | 45         | 44      |         |         |
| Drink                          |        |            |         |         |         |
| No                             | 83     | 45         | 38      | 0.131   |         |
| Yes                            | 29     | 11         | 18      |         |         |
| Smoke                          |        |            |         |         |         |
| No                             | 79     | 40         | 39      | 0.836   |         |
| Yes                            | 33     | 16         | 17      |         |         |
| Location                       |        |            |         |         |         |
| Proximal                       | 63     | 30         | 33      | 0.788   |         |
| Middle                         | 22     | 11         | 11      |         |         |
| Distal                         | 27     | 15         | 12      |         |         |
| Differentiation                |        |            |         |         |         |
| Moderate                       | 47     | 25         | 22      | 0.566   |         |
| Poor                           | 65     | 31         | 34      |         |         |
| Venous or perineural invasion  |        |            |         |         |         |
| Negative                       | 70     | 37         | 33      | 0.435   |         |
| Positive                       | 42     | 19         | 23      |         |         |
| Tumor size                     |        |            |         |         |         |
| ≤ 5cm                          | 72     | 39         | 33      | 0.237   |         |
| >5cm                           | 40     | 17         | 23      |         |         |
| TNM stage                      |        |            |         |         |         |
| I-II                           | 37     | 27         | 10      | 0.001   |         |
| III-IV                         | 75     | 29         | 46      |         |         |
| T stage                        |        |            |         |         |         |
| T1-2                           | 11     | 10         | 1       | 0.004   |         |
| T3-4                           | 101    | 46         | 55      |         |         |
| N stage                        |        |            |         |         |         |
| N0                             | 34     | 25         | 9       | 0.001   |         |
| N1-3                           | 78     | 31         | 47      |         |         |
| M stage                        |        |            |         |         |         |
| M0                             | 110    | 55         | 55      | 1.000   |         |
| M1                             | 2      | 1          | 1       |         |         |

No relationship between ARHGAP27P1 expression and other factors, for example, gender, age, drink, smoke, tumor location, tumor differentiation, tumor size or distant metastasis, was found in our study (Table 1). To further evaluate the value of ARHGAP27P1 in the prognosis of GC, we performed Kaplan-Meier survival analysis and log-rank tests. The results showed that downregulation of ARHGAP27P1 predicted a poorer OS in patients with GC (Figure 1D). Univariate and multivariate Cox regression analyses revealed that ARHGAP27P1 expression was an independent prognostic factor for OS (P = 0.039 and 0.048, respectively) in GC patients (Table 2). Thus, these data identified that low ARHGAP27P1 expression acted as an indicator for poor survival of GC patients.
Table 2. Univariate and multivariate analyses of overall survival in patients with GC.

| Features              | Univariate analysis | Multivariate analysis |
|-----------------------|---------------------|-----------------------|
|                       | HR (95% CI)         | P value               | HR (95% CI)         | P value               |
| Gender                | 1.068 (0.610–1.868) | 0.819                 | -                    | -                    |
| Age                   | 0.857 (0.500–1.468) | 0.573                 | -                    | -                    |
| Drink                 | 1.153 (0.674–1.974) | 0.603                 | -                    | -                    |
| Smoke                 | 0.835 (0.492–1.418) | 0.505                 | -                    | -                    |
| Differentiation       | 0.902 (0.556–1.463) | 0.675                 | -                    | -                    |
| Tumor location        | 1.394 (0.870–2.235) | 0.168                 | -                    | -                    |
| Tumor size            | 1.183 (0.725–1.931) | 0.501                 | -                    | -                    |
| TNM stage             | 1.655 (1.013–2.704) | 0.044                 | -                    | -                    |
| T stage               | 1.774 (0.714–4.412) | 0.217                 | -                    | -                    |
| N stage               | 1.675 (0.981–2.863) | 0.059                 | -                    | -                    |
| M stage               | 12.477 (2.766–56.276) | 0.001                | 10.538 (2.361–47.029) | 0.002                |
| ARHGAP27P1 expression | 0.608 (0.379–0.974) | 0.039                 | 0.620 (0.386–0.996) | 0.048                |

Plasma ARHGAP27P1 demonstrated moderate accuracy in diagnosis of GC

To further explore the potential utility of ARHGAP27P1 for GC diagnosis, we detected the expression of ARHGAP27P1 in plasma samples from 53 randomly selected GC patients and paired healthy donors. As shown in Figure 1E, the expression levels of plasma ARHGAP27P1 were significantly lower in GC patients than those in healthy controls. Consistently, downregulation of plasma ARHGAP27P1 was significantly associated with advanced TNM stage, increased invasion depth and lymphatic metastasis, respectively (Figure 1F). We then plotted ROC curve to assess the diagnostic value of plasma ARHGAP27P1 for GC. As demonstrated in Figure 1G, the AUC was 0.732 (95% CI, 0.636–0.827, P < 0.001), with the diagnostic sensitivity and specificity measuring 75.5 and 60.4% with the cut-off value of −2.321, respectively. These results indicated that plasma ARHGAP27P1 could be a potential predictor for GC diagnosis.

ARHGAP27P1 inhibited cell proliferation, cell cycle progression, migration and invasion in vitro

To gain insight into functional role of ARHGAP27P1 in GC, we first determined the expression of ARHGAP27P1 in diverse GC cell lines (MGC-803, AGS, HGC-27, BGC-823 and SGC-7901). Our data showed that ARHGAP27P1 was generally downregulated in the GC cells compared with that in GES-1 (Figure 2A). The relative low expression cell lines (SGC-7901 and AGS) were then selected as target cells for overexpression experiments, whereas the relative high expression cell line (HGC-27) were selected for knockdown experiments. The effectiveness of overexpression or knockdown was shown in Figure 2B, 3A. Cell counting assays showed that overexpression of ARHGAP27P1 led to growth retardation of SGC-7901 and AGS cells compared with the control cells (Figure 2C). Consistently, colony formation assays showed that the clonogenic survival was obviously decreased following ARHGAP27P1 overexpression. (Figure 2D). Next, flow cytometric analysis was performed to examine whether ARHGAP27P1 affected the proliferation of GC cells by altering cell cycle progression or apoptosis. The results revealed that ARHGAP27P1 overexpression induced apoptosis and cell cycle arrest at the G0/G1 phase (Figure 2E, 2F). Cell motility was further measured by wound-healing assays and transwell assays. As shown in Figure 2G–2I, ARHGAP27P1 overexpression impeded the capacity of wound closure, migration and invasion of SGC-7901 and AGS cells. Conversely, as opposed to the effects of ARHGAP27P1 overexpression, silencing of ARHGAP27P1 promoted the proliferation, cell cycle progression and cell motility of HGC-27 cells (Figure 3B–3G). Collectively, these findings suggested that ARHGAP27P1 rendered a less aggressive phenotype of GC cells.

ARHGAP27P1 promoted expression of p15, p16 and p57

To investigate the possible mechanisms by which ARHGAP27P1 regulates the biological phenotypes of GC cells, we screened the key genes associated with cell proliferation, apoptosis, cell cycle progression, angiogenesis, EMT and microenvironment remodeling. Consistent with the role of ARHGAP27P1 in cell cycle modulation, RT-qPCR and Western blot results showed that ARHGAP27P1 mainly affected the expression of...
CKIs including p15, p16 and p57, but not the expression of the other potential targets (Figure 4A–4C and Supplementary Figure 1A–1C). These results suggested that ARHGAP27P1 might contribute to cell cycle arrest through regulating expression of the tumor suppressor p15, p16 and p57. We then performed Spearman’s correlation analysis to assess the relationship between the expression of ARHGAP27P1 and that of p15 or p16 in 24 cases of GC tissues, respectively. As shown in Figure 4D and 4E, a positive correlation between the

![Figure 2. Overexpression of ARHGAP27P1 inhibited proliferation, cell cycle progression, invasion and migration, while induced apoptosis of GC cells.](image)

(A) RT-qPCR analysis of ARHGAP27P1 expression in GES-1 cells and different GC cells. (B) Relative ARHGAP27P1 levels in SGC-7901 and AGS cells transfected with pcDNA or pcDNA-ARHGAP27P1. (C) Cell proliferation in SGC-7901 and AGS cells transfected with pcDNA or pcDNA-ARHGAP27P1 was determined by cell counting assays. (D) Colony formation assays. (E) Cell apoptosis assays. (F) Cell cycle assays. (G) Wound-healing assays. (H) Transwell migration assays. (I) Transwell invasion assays. *P < 0.05, **P < 0.01, ***P < 0.001 versus GES-1 or vector.
expression of ARHGAP27P1 and that of p15 or p16 was also observed. In addition, we also detected the protein levels of p15, p16 and p57 in 5 cases of cancerous tissues with high ARHGAP27P1 expression and 5 cases with low ARHGAP27P1 expression. The results consistently showed that the ARHGAP27P1 expression inversely associated with the protein expression of p15, p16 and p57 (Figure 4G). Therefore, these data suggested that ARHGAP27P1 induced cell cycle arrest through regulating p15, p16 and p57.

**ARHGAP27P1 epigenetically activated p15, p16 and p57 transcription by binding to JMJD3**

Although we showed that ARHGAP27P1 affected the expression of p15, p16 and p57, the underlying mechanisms were still unclear. To address this issue, we firstly examined the subcellular localization of ARHGAP27P1 by fractionation assay and FISH assay. The results showed that ARHGAP27P1 mainly resided in the nucleus of GC cells (Figure 5A and 5B), suggesting that ARHGAP27P1 might play a major regulatory function at transcriptional level. Recent studies have reported that an increasing number of lncRNAs function in cooperation with chromatin modifying enzymes to promote epigenetic activation or silencing of gene expression [13]. The association of lncRNAs with PRC2 is among the best characterized models for this interaction [14, 15, 29]. It has been shown that approximately 20% of all human lncRNAs physically associate with PRC2, suggesting that lncRNAs may have a general role in recruiting PRC2 to their target

*Figure 3. Silencing of ARHGAP27P1 promoted proliferation, cell cycle progression, invasion and migration, and inhibited apoptosis of HGC-27 cells. Scramble siRNA (si-NC) or ARHGAP27P1 siRNA (si-ARHGAP27P1) was transfected into HGC-27 cells. (A) Knockdown efficiency of si-ARHGAP27P1 was determined by RT-qPCR. (B) Cell proliferation was determined by cell counting assays in ARHGAP27P1-silencing HGC-27 cells. (C) Colony formation assays. (D) Cell apoptosis assays. (E) Cell cycle assays. (F) Wound healing assays. (G) Transwell migration and invasion assays. *P < 0.05, **P < 0.01 versus si-NC.*
genes [14]. Other epigenetic modifiers including LSD1, SMYD3, WDR5, and KMT2C may also function as potential partners for lncRNA [16–18]. Therefore, we screened a panel of chromatin modifiers (JMJD3, EZH2, SMYD3, WDR5, KMT2C) that could potentially interact with lncRNAs by RIP experiments in SGC-7901 cells. The results showed that endogenous ARHGAP27P1 was specifically enriched in the anti-JMJD3 RIP fraction relative to the input compared to the IgG fraction (Figure 5C). These results suggested that ARHGAP27P1 could specifically bind to JMJD3 rather than other chromatin modifiers. Moreover, overexpression of ARHGAP27P1 enhanced the interaction of ARHGAP27P1 with JMJD3, an effect further reversed by silencing of JMJD3 (Figure 5D). JMJD3 (also named KDM6B) is a family member of the histone H3K27me3-specific demethylases that promote gene transcription mainly by acting as the rivals of PRC2 that otherwise catalytically adds the methyl groups to H3K27 [30, 31]. Here, we observed that enhanced interaction of ARHGAP27P1 with JMJD3 by ARHGAP27P1 overexpression led to remarkable demethylation of H3K27me3 in SGC-7901 and AGS cells, while ARHGAP27P1 silencing in HGC-27 cells showed the opposite effect (Figure 5G and 5H). JMJD3 is well documented to mediate the oncogenic stress-induced cell senescence via activating INK4 gene locus (INK4b-ARF-INK4a) and/or facilitating the regulatory activity of p53 on its target genes [32–34], suggesting an oncorepressor activity of JMJD3 in human malignancies via cell senescence induction. We then asked whether the interaction of ARHGAP27P1 with JMJD3 was required for ARHGAP27P1-mediated transcriptional activation of the CKIs. As expected, we observed that knockdown of JMJD3 reversed ARHGAP27P1-mediated H3K27me3 demethylation, thereby inhibiting p15, p16 and p57 expression in SGC-7901 and AGS cells (Figure 5F and 5G). We further showed that the levels of JMJD3, EZH2, SUZ12 and H3K4me3 were not affected by ARHGAP27P1 overexpression or knockdown. Consistently, the mRNA or protein levels of JMJD3 were not associated with ARHGAP27P1 expression levels in the detected cancerous tissues (Figure 4F and 4G). However, high expression levels of ARHGAP27P1 in cancerous tissues were associated with low levels of H3K27me3, suggesting that the interaction of ARHGAP27P1 with JMJD3 was crucial for H3K27me3 demethylation and transcriptional activation of p15, p16, and p57 (Figure 4G). Collectively, these results indicated that the association of ARHGAP27P1 with JMJD3 as well as the demethylation of H3K27me3 were specifically required for ARHGAP27P1-mediated activation of p15, p16 and p57.

Figure 4. ARHGAP27P1 affected the expression of p15, p16 and p57. (A) RT-qPCR analysis of the main CKIs including p15, p16, p21, p27 and p57 in HGC-27 cells transfected with si-ARHGAP27P1 or si-NC. (B and C) RT-qPCR analysis of the main CKIs in SGC-7901 or AGS transfected with pcDNA-ARHGAP27P1 or pcDNA. (D–F) Spearman’s correlation analysis of the relationship between the expression of ARHGAP27P1 and that of p15, p16 or JMJD3 in 24 GC tissues. (G) Western blot analysis of JMJD3, H3K27me3, p15, p16 and p57 in 5 cases of cancerous tissues with high ARHGAP27P1 expression and 5 cases with low ARHGAP27P1 expression. *P < 0.05 versus si-NC, vector or low ARHGAP27P1 expression.
Next, we sought to determine whether ARHGAP27P1 was involved in transcriptional activation through enrichment of JMJD3 to target gene promoters. ChIP assays showed that JMJD3 could bind to the p15 and p16 promoter regions (Figure 5E). Overexpression of ARHGAP27P1 enhanced JMJD3 binding to the p15 and p16 promoter regions, an effect further reversed by knockdown of JMJD3 (Figure 5E). Consistently, knockdown of JMJD3 counteracted the reduction in H3K27me3 binding to the p15 and p16 promoter regions by ARHGAP27P1 overexpression (Figure 5E). Taken together, these results suggested that ARHGAP27P1 acted to target JMJD3 occupancy and activity to epigenetically modulate the expression of p15, p16 and p57.

Figure 5. ARHGAP27P1 epigenetically activated p15 and p16 transcription by binding to JMJD3. (A) FISH analysis of the subcellular location of ARHGAP27P1 in AGS and HGC-27 cells. (B) Subcellular fractionation and RT-qPCR analysis to determine the ARHGAP27P1 location. U6 and β-actin were used as nucleus and cytoplasm markers, respectively. (C) RIP experiments were performed in SGC-7901 cells with IgG, anti-JMJD3, EZH2, SMYD3, WDR5 or KMT2C antibody, and the coprecipitated RNA was subjected to RT-qPCR analysis.
Silencing of JMJD3, p15 or p16 reversed the tumor suppressive effect of ARHGAP27P1

To further validate that JMJD3, p15 and p16 were involved in ARHGAP27P1-mediated phenotype changes in GC cells, we performed rescue experiments. As shown in Figure 6A–6D and Supplementary Figure 2A–2C, silencing of p15 or p16 in SGC-7901 and AGS cells partially reversed the inhibitory effects against proliferation, cell cycle progression, migration and invasion induced by ARHGAP27P1 overexpression. Double knockdown of p15 and p16 completely reversed the above effects by ARHGAP27P1 overexpression. Consistently, silencing of JMJD3 showed the comparable effects as double knockdown of p15 and p16. Collectively, these results indicated that ARHGAP27P1 inhibited proliferation, cell cycle progression, migration and invasion of GC cells through JMJD3/p15/p16 signaling pathway.

Overexpression of ARHGAP27P1 inhibited GC tumorigenesis in vivo

To determine whether ARHGAP27P1 affected tumor formation in vivo, we injected SGC-7901 cells stably transfected with ARHGAP27P1 or empty vector into nude mice. In consistent with in vitro results, tumor growth in the ARHGAP27P1 group was obviously slower than that in the vector group (Figure 7A). Up to 30 days after injection, the tumor weight in the ARHGAP27P1 group was significantly lower than that in the vector group (Figure 7B). Next, RT-qPCR assays confirmed high ARHGAP27P1 expression in tumor tissues collected from ARHGAP27P1 group rather than vector group (Figure 7C). Accordingly, the ARHGAP27P1 group associated with higher mRNA and protein expression levels of p15, p16, and p57 (Figure 7C–7E). This might be explained by decreased H3K27me3 levels following ARHGAP27P1 overexpression (Figure 7E). In addition, the expression of JMJD3, EZH2, SUZ12, or H3K4me3 was not affected by ARHGAP27P1 overexpression (Figure 7E). We also found that tumors developed from ARHGAP27P1-overexpressing cells showed less Ki-67 expression than tumors from vector group (Figure 7D). These data further supported a tumor suppressor role of ARHGAP27P1 in GC development.

DISCUSSION

In this study, we for the first time demonstrated a tumor suppressor role of ARHGAP27P1 in GC tumorigenesis. The ARHGAP27P1 expression was dramatically downregulated in GC tissues, and its low expression was closely related to advanced TNM stage, increased invasion depth and lymphatic metastasis. Low ARHGAP27P1 expression also independently predicted a poor OS of GC patients. In addition, circulating ARHGAP27P1 levels showed a moderate accuracy for diagnosis of GC. The tumorigenesis of GC is a very complicated pathological process, which involves malignant proliferation, abnormal apoptosis, migration and invasion of GC cells. Gain- and loss-of-function of ARHGAP27P1 assays revealed that ARHGAP27P1 inhibited GC cell proliferation, cell cycle progression, invasion, and migration and induced apoptosis. Therefore, ARHGAP27P1 might be explored as a potential diagnostic indicator and therapeutic target for GC. Nevertheless, given that the expressionional differences of ARHGAP27P1 between cancerous tissues/patients and noncancerous tissues/patients were not large, and that overexpression of ARHGAP27P1 did not completely abolish GC growth in vitro/in vivo, these finding were still worth further investigation.

As a novel documented lncRNA, the possible mechanisms by which ARHGAP27P1 regulated the biological phenotypes of GC were currently unclear. We screened the key genes associated with GC occurrence and progression and found that ARHGAP27P1 mainly affected the expression of p15, p16 and p57, but not the other candidate targets. P15, p16 and p57, which are major members of CKIs, bind directly to G1/S-transformed kinases (such as cyclin D/cyclin-dependent kinase (CDK)-4 and cyclin D/CDK6) to regulate a variety of cellular biological processes [35, 36]. Specifically, CDKs and their cyclin partners are positive regulators or accelerators that induce cell cycle progression; whereas, CKIs that act as brakes to stop cell cycle progression in response to regulatory signals are important negative regulators [37]. Transcription of CKIs is a key requirement for replicative or oncogene-induced senescence and constitutes an important barrier for tumor growth, while inactivation of CKIs has long been demonstrated to...
result in cell cycle disorders and boost cell proliferation in human cancers [38].

Our subcellular localization experiments identified a nuclear enrichment of ARHGAP27P1, suggesting that ARHGAP27P1 might play a major regulatory function at transcriptional level. Indeed, epigenetic modifiers are among the most frequent protein partners of IncRNAs that have been identified to date, of which histone methyltransferases and protein members of the PRC2

Figure 6. Silencing of JMJD3, p15 or p16 reversed the suppressive effect of ARHGAP27P1 in GC malignant progression. (A) ARHGAP27P1-overexpressing SGC-7901 and AGS cells were cotransfected with si-JMJD3, si-p15 or si-p16. Cell proliferation was determined by cell counting assays. (B) Colony formation assays. (C) Cell cycle assays and cell apoptosis assays. (D) Transwell migration and invasion assays. *P < 0.05 versus vector. #P < 0.05, ##P < 0.01 versus ARHGAP27P1.
have received considerable attention [14, 29, 31, 38]. It has been reported that approximately 20% of all human lncRNAs act to physically associate with PRC2, suggesting that lncRNAs may have a general role in recruiting PRC2 to their target genes [14]. Other epigenetic modifiers including LSD1, SMYD3, WDR5, KMT2C, SET1C, ING2 and PAQR3 may also function as potential candidates for lncRNA partners [16–18]. We screened a panel of chromatin modifiers (JMJD3, EZH2, SMYD3, WDR5, KMT2C) by RIP experiments and found that endogenous ARHGAP27P1 was enriched in the anti-JMJD3 RIP fraction compared to the IgG fraction. These results suggested that ARHGAP27P1 could specifically bind to JMJD3 rather than other chromatin modifiers. To the best of our knowledge, the role of JMJD3 as a lncRNA partner has not been reported before. Actually, previous studies regarding the expression and the role of JMJD3 in different cancers have shown discrepancies [30, 32, 33, 39–46]. For example, JMJD3 is well documented to mediate the oncogenic stress-induced cell senescence via activating INK4 gene locus, suggesting an oncorepressor activity of JMJD3 in human malignancies [30, 32, 33]. JMJD3 has also been shown to exert anti-acute myeloid leukemia (AML) effect by directly modulating H3K4 and H3K27 methylation levels to activate the expression of a number of key myelopoietic regulatory genes [39]. Consistently, JMJD3 deficiency was reported to promote malignant progression of human pancreatic carcinoma by decreasing the expression of C/EBPα [40], a potential inhibitory partner of E2F1. Moreover, JMJD3 expression levels are lower in various cancers, including CRC and liver carcinoma [43, 44]. On the other hand, an oncogenic role of JMJD3 has been documented in the case of T-cell acute lymphocytic leukemia (T-ALL) and myelodysplastic syndrome (MDS) [45, 46], which was
largely attributed to its specific partnership with NF-κB and NOTCH, two transcription factors whose overactivations are highly associated with the induction of multiple types of inflammatory cytokines and the proliferation of T cells. JMJD3 has also been recently shown upregulated in GC and ESCC, and its high expression predicted unfavorable survival [41, 42]. These observations implicate the existence of uncharacterized regulatory effects of JMJD3 on cell differentiation, survival, and proliferation, and suggest that the expression patterns of JMJD3 are context and cancer type specific. Given that the downstream targets of JMJD3 are huge in quantity and diverse in their functions, to investigate the specific downstream signaling activated by JMJD3 should be of vital importance according to different contexts. Apart from the expression levels of JMJD3, we argue that the interaction of JMJD3 with its different partners should also be taken into account to have a better understanding of this issue. Indeed, our results showed that overexpression of ARHGAP27P1 enhanced the interaction of ARHGAP27P1 with JMJD3, but not the expression levels of JMJD3. We further found that the increase in association of ARHGAP27P1 with JMJD3 led to remarkable decrease in H3K27me3 levels, thereby promoting p15, p16 and p57 transcription. Consistently, knockdown of JMJD3 reversed the above effects due to decrease in the interaction of ARHGAP27P1 with JMJD3. In addition, ChIP assays suggested that ARHGAP27P1 acted to target JMJD3 occupancy and activity to epigenetically modulate the expression of p15, p16 and p57. Therefore, it was not surprising that JMJD3, p15 and p16 were crucially involved in ARHGAP27P1-mediated phenotype changes of GC cells.

Taken together, our study identified a novel ARHGAP27P1-mediated regulator of the GC cell cycle and proliferation. ARHGAP27P1 serving as a member of JMJD3-mediated epigenetic regulation participated in the occurrence and development of GC. Our study may expand our understanding of the role of lncRNAs as an epigenetic regulator in GC, and provide a strategy and facilitate the development of lncRNA-directed diagnostics and therapeutics against this disease.

**MATERIALS AND METHODS**

**Patients and specimens**

Human GC specimens were obtained from the Affiliated People’s Hospital of Jiangsu University. This study was approved by the Institutional Ethical Committee of Jiangsu University, and informed consents were signed by all patients. Corresponding normal gastric tissue samples were taken from tissues that were located 5 cm away from tumor margin. All selected GC patients met the following inclusion criteria: (1) Patients were newly diagnosed to have GC with definite pathological evidence or radiological evidence; (2) No chemoradiotherapies were given before surgery. Plasma samples were also collected from each subject and were stored at −80°C before use. Plasma ARHGAP27P1 expression was detected in 53 randomly selected GC patients and 53 age and gender well matched healthy donors. Tumor stage was evaluated according to the eighth TNM staging (T for characteristics of the primary tumor, N for nodal involvement, and M for distant metastasis) of the International Union against Cancer (UICC)/American Joint Committee on Cancer (AJCC) system [47].

**Cell culture and transfection**

Five human GC cell lines SGC-7901, MGC-803, HGC-27, AGS and BGC-823 were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). The human normal gastric epithelial cell line (GES-1) was purchased from Procell Life Science and Technology (Wuhan, China). Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Thermo Fisher Scientific, USA) or Roswell Park Memorial Institute (RPMI) 1640 medium (Thermo Fisher Scientific, USA). All media were supplemented with 10% fetal bovine serum (FBS; Gibco, USA), 100 U/ml penicillin and 100μg/ml streptomycin (Gibco, USA) in humidified air at 37°C with 5% CO₂.

**RNA isolation and reverse transcription-quantitative polymerase chain reaction (RT-qPCR)**

Total RNA was extracted from tissues, plasma and cells of GC using Trizol Reagent (Sangon Biotech, Shanghai, China). For RT-qPCR, RNA was reversely transcribed into complementary DNA (cDNA) by using a Hiieff First Strand cDNA Synthesis Super Mix for RT-qPCR kit (Yeasen Biotech, Shanghai, China). Quantitative PCR analysis was carried out using the Hiieff qPCR SYBR Green Master Mix kit (Yeasen Biotech, Shanghai, China) on ABI 7500 real-time PCR system (Applied Biosystems, Singapore). The primer sequences were shown in Supplementary Table 1. β-actin or U6 was used as an endogenous control depending on the gene/sample detected. Relative expression levels were calculated by using the 2−ΔΔCt method.

** Constructs, synthesized oligos and treatment**

The ARHGAP27P1 overexpression plasmid was purchased from GenePharm (Shanghai, China). Briefly, the ARHGAP27P1 sequence was synthesized and inserted into the pcDNA3.1 (+) vector at the BamH1
sites. The small interfering RNAs (siRNAs) for ARHGAP27P1, JMJD3, p15 and p16, as well as scrambled negative control oligos, were also synthesized by GenePharm. The siRNA sequences are listed as follows: si-ARHGAP27P1 sense: 5′-GAGGAACGCUUCGACAAAGCTG-3′, antisense: 5′-AACUUUGUCAAGCGUUCUCCTT-3′; si-JMJD3 sense: 5′-UGACAAGGAAGACCUUUUATT-3′, antisense: 5′-AAUAAGGUCUCCUUGUACCTT-3′; si-p15 sense: 5′-CCCAACGGAAGUACCGGUUATT-3′, antisense: 5′-AACUAUUCGGUGCGUUUGGT-3′; si-NC sense: 5′-UUCUCGGAACCGUGUCACGUUATT-3′, antisense: 5′-ACUGACGACGUUCGGAATT-3′. For transfection, the cells were grown in a 12-well plate until confluence at 60%-80% and were transfected with the indicated molecules with Lipofectamine 2000 (Thermo Fisher Scientific), according to the manufacturer’s instructions. Forty-eight hours after transfection, the cells were ready for the following experiments.

Cell counting and colony formation assay

For proliferation assay, GC cells were seeded into 24-well plates (1 × 10^4 cells/well). The cells were collected and counted every day for 6 days. The results were plotted as cell growth curves. For colony formation assay, GC cells were placed in 6-well plates (1000 cells/well) and incubated at 37°C in a 5% CO2 humidified incubator. The culture medium was changed every 3 days. After 10 days, the colonies were washed with phosphate buffered saline (PBS), fixed with 4% paraformaldehyde for 10 minutes and stained with 0.5% crystal violet for 5 minutes. Visible colonies were counted and photographed. Experiments were carried out in triplicate independently.

Cell apoptosis and cell cycle analysis

For cell apoptosis assay, the indicated cells were stained with Annexin V-FITC/PI cell apoptosis detection kit (BD Pharmingen, San Diego, CA) and analyzed with a flow cytometer (BD FACSCalibur, San Jose, CA). Cells for cell cycle analysis were stained with PI using the CycleTEST PLUS DNA Reagent kit (BD Biosciences, Franklin Lakes, NJ, USA) according to the protocol. The percentages of cells in G0/G1, S and G2/M phase were counted and compared.

Migration and invasion assay

Migration and invasion assays were performed in transwell chambers without or with Matrigel-coated membranes, respectively. Briefly, GC cells were seeded with serum-free medium into the upper chambers at 5 × 10^4 cells/well, and the bottom chambers contained medium with 10% FBS. After incubation at 37°C with 5% CO2 for 24 hours, cells on the upper surface were removed with a cotton swab and cells on the lower surface were fixed with 4% paraformaldehyde for 10 minutes and stained with 0.5% crystal violet for 5 minutes. Cells were photographed and counted under an inverted microscope (Nikon, Japan).

Wound-healing assays

Indicated cells were plated to confluence in 6-well plates. Streaks across the plate were created in the monolayer with a pipette tip, followed by three washes with PBS. The cells were then cultured for hours with medium containing 1% FBS. To ensure documentation of the same region, the wells were marked across the wounded area. Progression of migration was observed and photographed at 0 and 24 hours after wounding. The distance between the two edges of the scratch was measured and calculated.

Subcellular fractionation

The separation of cytoplasmic and nuclear fractions was performed using the PARIS Kit (Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s instructions.

Fluorescence In Situ Hybridization (FISH)

The ARHGAP27P1 FISH probes (probe 1#: 5′-GCTTGCCCAGGGCTGAGGACAACGAGGAA-3′, Probe 2#: 5′-GTCTGTGCTGGGATGCTGGCAG-3′) were designed and synthesized by GenePharm (Shanghai, China). Briefly, cells were washed and fixed with 4% paraformaldehyde for 10 min. After treatment with protease K (2 μg/mL), glycine and phthalide reagent, the cells were incubated with 100 μL of pre-hybridization solution at 42°C for 1 h. After that, the cells were hybridized with 100 μL of hybridization solution containing probes (10 μM) at 73°C for 5 min and 37°C for 12–16 h in a humidified incubator. Then, the cells were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) and observed under a fluorescence microscope (Leica, SP8 laser confocal microscope).

Western blot

Equal amounts of protein samples were separated by 8%-15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and were transferred to nitrocellulose membranes. Bands were probed immunologically using antibodies against JMJD3, EZH2, SUZ12, H3K4me3, H3K27me3, p15, p16, p57 and GAPDH. Antibodies against JMJD3, EZH2, SUZ12,
H3K4me3, H3K27me3 were purchased from Cell signaling Technology (MA, USA). Antibodies against p15, p16, p57 and GAPDH were purchased from Enogene (Nanjing, China). Signals were detected using an enhanced chemiluminescence (ECL) system according to the manufacturer’s instructions.

Immunohistochemistry
Briefly, sections were deparaffinized, rehydrated, and incubated in sodium citrate buffer for antigen retrieval. Endogenous peroxidase was blocked by incubation in 3% H2O2 for 10 min at room temperature. The sections were then incubated with antibodies against p15, p16, JMJD3 or Ki-67 (Santa Cruz, CA) overnight at 4°C. Finally, HRP-conjugated secondary antibody and dianinobenzidine (DAB) solution (Solarbio, Beijing, China) were used to detect the signals. Slides were photographed under a microscope.

Chromatin immunoprecipitation (ChIP) assays
ChIP experiment was conducted using the EZ-CHIP KIT (Millipore, Billerica, MA, USA). Briefly, the DNA-protein crosslink was built through GC cells’ incubation with formaldehyde. Cell lysates were then sonicated to generate chromatin fragments of 200-300 bps and immunoprecipitated with anti-JMJD3 or H3K27me3 antibodies. Precipitated chromatin DNA was recovered and analyzed by qPCR. The ChIP primer sequences for p15 and p16 are listed in Supplementary Table 1. The results were calculated as a percentage relative to the input DNA.

RNA immunoprecipitation (RIP)
RIP experiments were performed using a Magna RIP RNA-Binding Protein Immunoprecipitation Kit (Millipore, USA) according to the manufacturer’s instructions. Antibodies for JMJD3, EZH2, SMYD3, WDR5 and KMT2C RIP assays were from Cell signaling (MA, USA).

Tumor xenograft experiment
The procedures for animal studies were approved by the Animal Use and Care Committee of Jiangsu University. Four-week-old athymic BALB/c mice were maintained under specific pathogen-free conditions. Briefly, SGC-7901 cells stably transfected with vector or ARHGAP27P1 were selected by G418 (Invitrogen, Carlsbad, CA). Approximately 2 × 10^6 SGC-7901 cells were resuspended with 0.2 ml PBS and injected into the dorsal right flank of each nude mouse (6 mice per group). Tumor volumes were calculated as 0.5 × length × width^2 every 3 days. After 30 days, the mice were sacrificed, and tumors were excised, weighed, and immediately frozen at -80°C for future use.

Statistical analysis
All statistical analyses were conducted with SPSS 24.0 software (IBM, SPSS, USA). The significance of differences between groups was estimated by Student’s t-tests or one-way analysis of variance (ANOVA). The associations between ARHGAP27P1 and the clinicopathological features were analyzed by the Pearson χ^2 test. The log-rank test was used to identify statistically significant differences between survival curves. Univariate and multivariate Cox proportional hazards analyses were carried out to evaluate the independent risk factors for the OS of patients. Receiver operating characteristic (ROC) curve analysis was used to investigate the predictive value of ARHGAP27P1 in differentiating patients with GC from the noncancerous population. The area under the ROC curve (AUC) indicated the accuracy of diagnosis. A P values less than 0.05 was considered statistically significant.

CONFLICTS OF INTEREST
The authors declare that they have no conflicts of interest.

FUNDING
This study was supported by the National Science Foundation of China (8150193, 81802409), the Natural Science Foundation of Jiangsu Province (BK20161353), the Key Youth Talents Program in Health, Jiangsu Province (QNRC2016454), and the Social Development Foundation of Zhenjiang (SH2018072, SH2018057). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394–424. https://doi.org/10.3322/caac.21492 PMID:30207593
2. Ajani JA, Lee J, Sano T, Janjigian YY, Fan D, Song S. Gastric adenocarcinoma. Nat Rev Dis Primers. 2017; 3:17036. https://doi.org/10.1038/nrdp.2017.36 PMID:28569272
3. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu Q, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66:115–32. https://doi.org/10.3322/caac.21338 PMID:26808342

4. Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2014; 15:7–21. https://doi.org/10.1038/nrg3606 PMID:24296535

5. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009; 10:155–59. https://doi.org/10.1038/nrg2521 PMID:19188922

6. Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev. 2009; 23:1494–504. https://doi.org/10.1101/gad.1800909 PMID:19571179

7. Geisler S, Coller J. RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol. 2013; 14:699–712. https://doi.org/10.1038/nrm3679 PMID:24105322

8. Wang J, Zhang X, Chen W, Hu X, Li J, Liu C. Regulatory roles of long noncoding RNAs implicated in cancer hallmarks. Int J Cancer. 2019. [Epub ahead of print]. https://doi.org/10.1002/ijc.32277 PMID:30873588

9. Chandra Gupta S, Nandan Tripathi Y. Potential of long non-coding RNAs in cancer patients: from biomarkers to therapeutic targets. Int J Cancer. 2017; 140:1955–67. https://doi.org/10.1002/ijc.30546 PMID:27925173

10. Bartonicek N, Maag JL, Dinger ME. Long noncoding RNAs in cancer: mechanisms of action and technological advancements. Mol Cancer. 2016; 15:43. https://doi.org/10.1186/s12943-016-0530-6 PMID:27233618

11. YiRen H, YingCong Y, Sunwu Y, Keqin L, Xiaochun T, Senrui C, Ende C, Xizhou L, Yanfan C. Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer. Mol Cancer. 2017; 16:174. https://doi.org/10.1186/s12943-017-0743-3 PMID:29162158

12. Liu Y, Zhao J, Zhang W, Gan J, Hu C, Huang G, Zhang Y. LncRNA GAS5 enhances G1 cell cycle arrest via binding to YBX1 to regulate p21 expression in stomach cancer. Sci Rep. 2015; 5:10159. https://doi.org/10.1038/srep10159 PMID:25959498

13. Hanly DJ, Esteller M, Berdasco M. Interplay between long non-coding RNAs and epigenetic machinery: emerging targets in cancer? Philos Trans R Soc Lond B Biol Sci. 2018; 373:373. https://doi.org/10.1098/rstb.2017.0074 PMID:29685978

14. Khalil AM, Gutmann M, Huarte M, Garber M, Raj A, Rivea Morales D, Thomas K, Presser A, Bernstein BE, van Oudenaarden A, Regev A, Lander ES, Rinn JL. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci USA. 2009; 106:11667–72. https://doi.org/10.1073/pnas.0904715106 PMID:19571010

15. Zhang G, Xu Y, Wang S, Gong Z, Zou C, Zhang H, Ma G, Zhang W, Jiang P. LncRNA SNHG17 promotes gastric cancer progression by epigenetically silencing of p15 and p57. J Cell Physiol. 2019; 234:5163–74. https://doi.org/10.1002/jcp.27320 PMID:30256413

16. Liu YW, Xia R, Lu K, Xie M, Yang F, Sun M, De W, Wang C, Ji G. LncRNA FEZF1-AS1 represses p21 expression to promote gastric cancer proliferation through LSD1-Mediated H3K4me2 demethylation. Mol Cancer. 2017; 16:39. https://doi.org/10.1186/s12943-017-0588-9 PMID:28209170

17. Zhang XD, Huang GW, Xie YH, He JZ, Guo JC, Xu XE, Liao LD, Xie YM, Song YM, Li EM, Xu LY. The interaction of lncRNA EZR-AS1 with SMYD3 maintains overexpression of EZR in ESCC cells. Nucleic Acids Res. 2018; 46:1793–809. https://doi.org/10.1093/nar/gkx1259 PMID:29253179

18. Gu P, Chen X, Xie R, Han J, Xie W, Wang B, Dong W, Chen C, Yang M, Jiang J, Chen Z, Huang J, Lin T. LncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5. Mol Ther. 2017; 25:1959–1973. https://doi.org/10.1016/j.ymthe.2017.04.016 PMID:28487115

19. Nakamura F. FilGAP and its close relatives: a mediator of Rho-Rac antagonism that regulates cell morphology and migration. Biochem J. 2013; 453:17–25. https://doi.org/10.1042/BJ20130290 PMID:23763313

20. Clay MR, Halloran MC. Rho activation is apically restricted by Arhgap1 in neural crest cells and drives epithelial-to-mesenchymal transition. Development. 2013; 140:3198–209. https://doi.org/10.1242/dev.095448 PMID:23804498

21. Katoh M, Katoh M. Identification and characterization of human KIAA1391 and mouse Kiaa1391 genes encoding novel RhoGAP family proteins with RA domain and ANXL repeats. Int J Oncol. 2003; 23:1471–76. https://doi.org/10.3892/ijo.23.5.1471 PMID:14532992

22. Johnstone CN, Castellvi-Bel S, Chang LM, Bessa X, Nakagawa H, Harada H, Sung RK, Piquè JM, Castells A, Rustgi AK. ARHGAP8 is a novel member of the RHOGAP
family related to ARHGAP1/CDC42GAP/p50RHOGAP: mutation and expression analyses in colorectal and breast cancers. Gene. 2004; 336:59–71. https://doi.org/10.1016/j.gene.2004.01.025 PMID:15225876

23. Wang J, Qian J, Hu Y, Kong X, Chen H, Shi Q, Jiang L, Wu C, Zou W, Chen Y, Xu J, Fang JY. ArhGAP30 promotes p53 acetylation and function in colorectal cancer. Nat Commun. 2014; 5:4735. https://doi.org/10.1038/ncomms5735 PMID:25156493

24. Lister N, Shevchenko G, Walshe JL, Groen J, Johnsson P, Vidarsdóttir L, Grander D, Ataide SF, Morris KV. The molecular dynamics of long noncoding RNA control of transcription in PTEN and its pseudogene. Proc Natl Acad Sci USA. 2017; 114:9942–47. https://doi.org/10.1073/pnas.1621490114 PMID:28847966

25. Stewart GL, Enfield KS, Sage AP, Martinez VD, Minatel BC, Pewarchuk ME, Marshall EA, Lam WL. Aberrant Expression of Pseudogene-Derived IncRNAs as an Alternative Mechanism of Cancer Gene Regulation in Lung Adenocarcinoma. Front Genet. 2019; 10:138. https://doi.org/10.3389/fgene.2019.00138 PMID:30894871

26. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell. 2011; 146:353–58. https://doi.org/10.1016/j.cell.2011.07.014 PMID:21802130

27. Pink RC, Wicks K, Caley DP, Punch EK, Jacobs L, Carter DR. Pseudogenes: pseudo-functional or key regulators in health and disease? RNA. 2011; 17:792–98. https://doi.org/10.1261/rna.2658311 PMID:21398401

28. Poliseno L. Pseudogenes: newly discovered players in human cancer. Sci Signal. 2012; 5:re5. https://doi.org/10.1126/scisignal.2002858 PMID:22990117

29. Yan J, Dutta B, Hee YT, Chng WJ. Towards understanding of PRC2 binding to RNA. RNA Biol. 2019; 16:176–84. https://doi.org/10.1080/15476286.2019.1565283 PMID:30608221

30. Salminen A, Kaarniranta K, Hiltunen M, Kauppinen A. Histone demethylase Jumonji D3 (JMJD3/KDM6B) at the nexus of epigenetic regulation of inflammation and the aging process. J Mol Med (Berl). 2014; 92:1035–43. https://doi.org/10.1007/s00109-014-1182-x PMID:24925089

31. Swigut T, Wysocka J. H3K27 demethylases, at long last. Cell. 2007; 131:29–32. https://doi.org/10.1016/j.cell.2007.09.026 PMID:17923085

32. Agger K, Cloos PA, Rudkjæer L, Williams K, Andersen G, Christensen J, Helin K. The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stress-induced senescence. Genes Dev. 2009; 23:1171–76. https://doi.org/10.1101/gad.510809 PMID:19451217

33. Martinelli P, Bonetti P, Sironi C, Pruneri G, Fumagalli C, Raviele PR, Volorio S, Pileri S, Chiarle R, McDuff FK, Tusi BK, Turner SD, Inghirami G, et al. The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway. Blood. 2011; 117:6617–26. https://doi.org/10.1182/blood-2010-08-301135 PMID:21518927

34. Akdemir KC, Jain AK, Allton K, Aronow B, Xu X, Cooney AJ, Li W, Barton MC. Genome-wide profiling reveals stimulus-specific functions of p53 during differentiation and DNA damage of human embryonic stem cells. Nucleic Acids Res. 2014; 42:205–23. https://doi.org/10.1093/nar/gkt866 PMID:24078252

35. Harper JW. Cyclin dependent kinase inhibitors. Cancer Surv. 1997; 29:91–107. PMID:9338098

36. Bockstaele L, Kooken H, Libert F, Paternot S, Dumont JE, de Launoit Y, Roger PP, Coulonval K. Regulated activating Thr172 phosphorylation of cyclin-dependent kinase 4(CDK4): its relationship with cyclins and CDK “inhibitors”. Mol Cell Biol. 2006; 26:5070–85. https://doi.org/10.1128/MCB.02006-05 PMID:16782892

37. Park MT, Lee SJ. Cell cycle and cancer. J Biochem Mol Biol. 2003; 36:60–65. https://doi.org/10.5483/BMBRep.2003.36.1.060 PMID:12542976

38. Aguilo F, Zhou MM, Walsh MJ. Long noncoding RNA, polycomb, and the ghosts haunting INK4b-ARF-INK4a expression. Cancer Res. 2011; 71:5365–69. https://doi.org/10.1158/0008-5472.CAN-10-4379 PMID:21828241

39. Yu SH, Zhu KY, Chen J, Liu XZ, Xu PF, Zhang W, Yan L, Guo HZ, Zhu J. JMJD3 facilitates C/EBPβ-centered transcriptional program to exert oncopressor activity in AML. Nat Commun. 2018; 9:3369. https://doi.org/10.1038/s41467-018-05548-z PMID:30135572

40. Yamamoto K, Tateishi K, Kudo Y, Sato T, Yamamoto S, Miyabayashi K, Matsusaka K, Asaoka Y, Iiichi H, Hirata Y, Otsuka M, Nakai Y, Isayama H, et al. Loss of histone demethylase KDM6B enhances aggressiveness of
pancreatic cancer through downregulation of C/EBPα. Carcinogenesis. 2014; 35:2404–14. https://doi.org/10.1093/carcin/bgu136 PMID:24947179

41. Li SH, Lu HI, Chen YH, Lo CM, Huang WT, Tien WY, Lan YC, Tsai HT, Chen CH. JMJD3 expression is an independent prognosticator in patients with esophageal squamous cell carcinoma. Surgery. 2019; 165:946–52. https://doi.org/10.1016/j.surg.2018.11.015 PMID:30678869

42. Xu Z, Xia Y, Xiao Z, Jia Y, Li L, Jin Y, Zhao Q, Wan L, Yi T, Yu Y, Wen Q, Zhu Y, Qin B, et al. Comprehensive profiling of JMJD3 in gastric cancer and its influence on patient survival. Sci Rep. 2019; 9:868. https://doi.org/10.1038/s41598-018-37340-w PMID:30696880

43. Tokunaga R, Sakamoto Y, Nakagawa S, Miyake K, Izumi D, Kosumi K, Taki K, Higashi T, Imamura Y, Ishimoto T, lwatsuki M, Baba Y, Miyamoto Y, et al. The Prognostic Significance of Histone Lysine Demethylase JMJD3/KDM6B in Colorectal Cancer. Ann Surg Oncol. 2016; 23:678–85. https://doi.org/10.1245/s10434-015-4879-3 PMID:26416711

44. Tang B, Qi G, Tang F, Yuan S, Wang Z, Liang X, Li B, Yu S, Liu J, Huang Q, Wei Y, Zhai R, Lei B, et al. Aberrant JMJD3 Expression Upregulates Slug to Promote Migration, Invasion, and Stem Cell-Like Behaviors in Hepatocellular Carcinoma. Cancer Res. 2016; 76:6520–32. https://doi.org/10.1158/0008-5472.CAN-15-3029 PMID:27651311

45. Wei Y, Chen R, Dimicoli S, Bueso-Ramos C, Neuberg D, Pierce S, Wang H, Yang H, Jia Y, Zheng H, Fang Z, Nguyen M, Ganan-Gomez I, et al. Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells. Leukemia. 2013; 27:2177–86. https://doi.org/10.1038/leu.2013.91 PMID:23538751

46. Ntziachristos P, Tsirigos A, Welstead GG, Trimarchi T, Bakogianni S, Xu L, Loizou E, Holmfeldt L, Strikoudis A, King B, Mullenders J, Beckford J, Nedjic J, et al. Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. Nature. 2014; 514:513–17. https://doi.org/10.1038/nature13605 PMID:25132549

47. In H, Solsky I, Palis B, Langdon-Embry M, Ajani J, Sano T. Validation of the 8th Edition of the AJCC TNM Staging System for Gastric Cancer using the National Cancer Database. Ann Surg Oncol. 2017; 24:3683–3691. https://doi.org/10.1245/s10434-017-6078-x PMID:28895113
Supplementary Figure 1. ARHGAP27P1 showed minimal effects on the expression of diverse potential genes involved in GC progression. (A) RT-qPCR analysis of p53, CDK2, CDK4, Wnt1, c-Myc, PTEN, PDCD4, Bcl-2, Bcl-xL, Bax, TWIST1, E-cad, Slug, N-cad, Vimentin, MMP1, MMP9, BNIP3, VEGF and EGFR in HGC-27 cells transfected with si-ARHGAP27P1 or si-NC. (B and C) RT-qPCR analysis of the above genes in SGC-7901 or AGS transfected with pcDNA-ARHGAP27P1 or pcDNA.
Supplementary Figure 2. Silencing of JMJD3, p15 or p16 counteracted the tumor suppressive effect of ARHGAP27P. (A) ARHGAP27P1-overexpressing AGS cells were cotransfected with si-JMJD3, si-p15 or si-p16. Cell proliferation was determined by colony formation assays. (B) Wound-healing assays for ARHGAP27P1-overexpressing SGC-7901 or AGS cells cotransfected with si-JMJD3, si-p15 or si-p16. (C) Migration and invasion assays for ARHGAP27P1-overexpressing AGS cells cotransfected with si-JMJD3, si-p15 or si-p16. *P < 0.05 versus vector. #P < 0.05, ##P < 0.01 versus ARHGAP27P1.
**Supplementary Table 1. Gene primer sequences.**

| Gene name  | Forward(5′-3′)          | Reverse(5′-3′)          |
|------------|-------------------------|-------------------------|
| ARHGAP27P1 | CGGGTCCCCTTCTTATCCAG    | ATTG GCCACCTGAAATCACCC  |
| p15        | GGGAGGGTAATGAAGCTGAG    | GGCCGTAAAACCTAAGCAGACT |
| p16        | CTACTGAGGGAGCCAGGCTCT   | CTGCCAATCGCTAGACCTT    |
| p21        | TGTGGACCTGTACCACCTCCTTGTA | GGCCTTTGGAGGTAGAAATCT  |
| p27        | GGCAAGTACGAGTGCAAAGAG   | AATGCGTGTCCTGAGGTTAGC  |
| p57        | TGAACGCCGAGGACACGAA     | ACCGAGTCGCTGCCTCAA     |
| p53        | GCTCTGACTGTACCACCTCCTC | CTCTCGGAACACTTCAAGAC   |
| CDK2       | GTACCCTCCTGGGAATGAGAT   | CGAAATCGCTGTAAGGTC     |
| CDK4       | CTGGTGGTTGAGCATGTAGACC  | GATCCTTGATCTGGCTGGCT   |
| Wnt1       | ATCTTCCGCTATCACCTCCGC  | GGCGGAAGTCAATGTGGCCT   |
| c-Myc      | GGACTTGTTGGCGAAACAGAC  | CTCAGCCAAGGGTGTGAGG    |
| PTEN       | GCACGTGTGTTTCCAACAAGATG | GCAGACCACAAACCTGAGGATT |
| Bcl-2      | CTGGGATGCTTTTGTGGAAC    | CAGGCATTTGACCTTTAAGT   |
| PDCD4      | GCTACCGTGCTTCTGAGATAT   | GGCAATGTGCTAGCCTGAT    |
| Bax        | GTCCGGCTTTTTCATCTGGCC   | AGTCGCTCTAGTAGCTCGG    |
| Bcl-xL     | CCCAGAAAGGATACGCTGGG    | GCGATCCGACTCCAATAC     |
| TWIST1     | GGAGTCCGCAGTCTTACAGG    | TCTGGAGGACCTGGTAAAGG   |
| E-cad      | GGTCTGTCTATGGAAAGGTGCTC | CAGGATCTTGGTGGAGGATG   |
| Slug       | TGTCGACATAGGTAATGTGAGCC | TGAGCCCTCAGATTTGACTG   |
| N-cad      | TCAACTGCAACCGTGTCTGT    | ATCGATCTGGGTCCTGAGC    |
| MMP1       | CACAACACACAAAAAGGTTG    | TCGCCAATTTGTAAGCAGC    |
| MMP9       | CAAGTGGCACCACCAACCATCA | CCCGCAGACAGTCCTCCAG    |
| Vimentin   | TGGACCAGCTAAACACGCAGC   | GCCAGAGACGCTTACCAAC    |
| BNIP3      | TTTAAAACACCGAGAGAGGAC   | CTGGTGAGGTGTCAGGAGC    |
| VEGF       | GAGATGAGCTCTCTACAGCAA   | TCACGGCTCGCTGAGACC     |
| EGFR       | CCGTGCTTGGAAATCGCAGG    | CGATGGACGGAGATCTAGG    |
| JMJD3      | ACACCTTGAGCAACACAGCAGC  | TTCAGAAGTTGAGCCCTCTCC  |
| β-actin    | CATTCCCAATATGAGATGCCGTT | TGGAGGCTTGAGGAGGACT    |
| U6         | CTCCGCTTCGGCAGCACCA     | AACGCCCTCAAGATTTGCCT   |
| p15-ChIP   | TCGAGTTAAGCCTACCATGACAG | AACTCTTCTGGGCAATGGTTC  |
| p16-ChIP   | AAGAAGAAGCCATCTTCCCTATG | GGCTTTGGAGTGCCTTCAC   |